Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A.
While the gene delivery vehicle is critical for the efficacy of human factor VIII gene therapy, optimization of the potency and duration of the factor VIII gene that is delivered is equally important in light of the poor transcription and translation characteristics of this gene. We discuss here a systematic approach to optimization of factor VIII complementary DNA expression by analysis of specific elements engineered into the transcription unit and other positions in the expression plasmid. Within the transcription unit we have engineered different 5' and 3' sequence modifications and tested them for factor VIII expression in human liver cells. These changes incorporate liver-specific promoter and enhancer sequences and regulatory elements affecting RNA export. Specifically, the thyroid hormone-binding globulin promoter and alpha 1 microglobulin/bikunin enhancer were tested and a synthetic 5' intron was compared to a 3' post-transcriptional regulatory element on factor VIII expression levels. For translation optimization, a leader sequence was designed to be of optimum length, have no RNA secondary structure and contain the optimal translation initiation sequence. Finally, we discuss areas for plasmid optimization, which include removal of near-consensus splicing sequences, the inclusion of strong transcription termination elements and the use of autonomous replicating plasmid sequences for episomal maintenance and enhanced plasmid retention for duration of gene expression.
Ill
C R
CR
Division of Gene Therapy, Immune Response Corporation, Carlsbad, California 92008, USA.
Yang
C Q
CQ
Bidlingmaier
S M
SM
Gonzales
J N
JN
Burns
D S
DS
Bartholomew
R M
RM
Scuderi
P
P
D006528:Carcinoma, Hepatocellular; D018076:DNA, Complementary / Q000235:genetics*; D005169:Factor VIII / Q000235:genetics* / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D015316:Genetic Therapy / Q000379:methods*; D006467:Hemophilia A / Q000235:genetics*; D006801:Humans; D010957:Plasmids / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D018076:DNA, Complementary; D005169:Factor VIII